TRUP vs. OSCR, GABC, CSR, PLYM, QCRH, AMSF, EFC, RBCAA, ROOT, and ECPG
Should you be buying Trupanion stock or one of its competitors? The main competitors of Trupanion include Oscar Health (OSCR), German American Bancorp (GABC), Centerspace (CSR), Plymouth Industrial REIT (PLYM), QCR (QCRH), AMERISAFE (AMSF), Ellington Financial (EFC), Republic Bancorp (RBCAA), Root (ROOT), and Encore Capital Group (ECPG). These companies are all part of the "finance" sector.
Trupanion (NASDAQ:TRUP) and Oscar Health (NYSE:OSCR) are both finance companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
In the previous week, Trupanion had 7 more articles in the media than Oscar Health. MarketBeat recorded 10 mentions for Trupanion and 3 mentions for Oscar Health. Oscar Health's average media sentiment score of 1.21 beat Trupanion's score of 0.53 indicating that Oscar Health is being referred to more favorably in the news media.
Trupanion has higher earnings, but lower revenue than Oscar Health. Trupanion is trading at a lower price-to-earnings ratio than Oscar Health, indicating that it is currently the more affordable of the two stocks.
75.7% of Oscar Health shares are held by institutional investors. 5.8% of Trupanion shares are held by company insiders. Comparatively, 25.5% of Oscar Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Trupanion received 494 more outperform votes than Oscar Health when rated by MarketBeat users. Likewise, 66.41% of users gave Trupanion an outperform vote while only 53.85% of users gave Oscar Health an outperform vote.
Trupanion currently has a consensus target price of $33.20, suggesting a potential upside of 42.00%. Oscar Health has a consensus target price of $13.50, suggesting a potential downside of 20.68%. Given Trupanion's higher possible upside, equities analysts clearly believe Trupanion is more favorable than Oscar Health.
Trupanion has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Oscar Health has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.
Trupanion has a net margin of -4.03% compared to Oscar Health's net margin of -4.62%. Trupanion's return on equity of -15.19% beat Oscar Health's return on equity.
Summary
Trupanion beats Oscar Health on 10 of the 18 factors compared between the two stocks.
Get Trupanion News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRUP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trupanion Competitors List
Related Companies and Tools
